<DOC>
	<DOCNO>NCT01497093</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) pomalidomide combination bortezomib low-dose dexamethasone subject relapse refractory multiple myeloma</brief_summary>
	<brief_title>Study Determine Maximum Tolerated Dose Combination Pomalidomide , Bortezomib Low-Dose Dexamethasone Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>A 3 + 3 design utilized determine MTD POM + IV BTZ + LD-DEX combination treatment 21-day treatment cycle . DLT assess determine MTD first treatment cycle . Once MTD determine maximum plan dose ( MPD ) reach without reach MTD POM + IV BTZ + LD-DEX , cohort 6 additional subject treat MTD/MPD level confirm safety ass preliminary efficacy . An additional cohort subject enrol explore safety combination POM + BTZ + LD-DEX use SQ BTZ . Subject cohort receive POM + BTZ + LD-DEX MTD/MPD level per MTD determination part study , except , BTZ administer subcutaneously ( SQ ) instead intravenously ( IV ) . In , Protocol Amendment # 4 , number subject enrol enrolled exploratory SQ BTZ cohort increase 6 12 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : 1 . Must ≥ 18 year time signing informed consent form . 2 . Subjects must document diagnosis multiple myeloma measurable disease ( serum Mprotein ≥ 0.5 g/dL urine Mprotein ≥ 200 mg/24 hour ) . 3 . Subjects must least 1 great 4 prior antimyeloma therapy . 4 . Subjects must receive least 2 consecutive cycle prior treatment lenalidomide must refractory last lenalidomidecontaining regimen ( either single agent combination ) . 5 . Subjects must receive least 2 consecutive cycle prior treatment proteasome inhibitorcontaining regimen , must refractory bortezomib ( either single agent combination ) . 6 . Subjects must document progression last antimyeloma therapy . 7 . Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . Exclusion criterion : 1 . Subjects refractory bortezomib either single agent combination . 2 . Subjects peripheral neuropathy ≥ Grade 2 3 . Subjects nonsecretory multiple myeloma 4 . Subjects follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL Platelet count &lt; 75,000/µL subject &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/ µL subject ≥ 50 % bone marrow nucleate cell plasma cell Creatinine Clearance &lt; 45 mL/min accord CockcroftGault formula Corrected serum calcium &gt; 14 mg/dL ( &gt; 3.5 mmol/L ) Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior RBC transfusion recombinant human erythropoietin use permit ) Serum glutamic oxaloacetic transaminase ( SGOT ) / aspartate aminotransferase ( AST ) Transaminase , serum glutamic pyruvic ( SGPT ) / alanine aminotransferase ( ALT ) &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 1.5 x ULN 5 . Subjects prior history malignancy , MM , unless subject free disease ≥ 5 year . Except follow : Basal cell carcinoma skin , Squamous cell carcinoma skin , Carcinoma situ cervix , Carcinoma situ breast , Incidental histologic find prostate cancer ( T1a T1b use TNM [ tumor , node , metastasis ] clinical staging system ) prostate cancer curative . 6 . Subjects previous therapy Pomalidomide 7 . Subjects hypersensitivity thalidomide , lenalidomide , bortezomib , boron , mannitol , dexamethasone 8 . Subjects ≥ Grade 3 rash prior thalidomide lenalidomide therapy 9 . Subjects follow within last 14 day initiation study treatment : Plasmapheresis , Major surgery ( kyphoplasty consider major surgery ) , Radiation therapy , Any antimyeloma drug therapy 10 . Subjects receive investigational agent within 28 day 5 halflives ( whichever longer ) treatment 11 . Pregnant breastfeeding female 12 . Men woman childbearing potential sexual partner unwilling employ adequate contraception . 13 . Subjects know Human immunodeficiency virus ( HIV ) positivity active infectious hepatitis A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
	<keyword>Refractory Myeloma</keyword>
	<keyword>Resistant Multiple Myeloma</keyword>
	<keyword>Treatment-resistant Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Lenalidomide-resistant</keyword>
</DOC>